RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies
The SARS-CoV-2 pandemic still represents a threat for immunosuppressed and hematological malignancy (HM) bearing patients, causing increased morbidity and mortality. Given the low anti-SARSCoV-2 IgG titers post-vaccination, the COVID-19 threat prompted the prophylactic use of engineered anti-SARS-Co...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2022.2163785 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846102238825545728 |
|---|---|
| author | Camille Bigenwald Yacine Haddad Cassandra Thelemaque Agathe Carrier Roxanne Birebent Pierre Ly Caroline Flament Imran Lahmar Eric de Sousa Markus Maeurer Makoto Miyara Tarek Assi Cristina Castilla-Llorente Christophe Willekens Céline Fayemi Julien Lazarovici Aurélien Marabelle Lisa Derosa Vincent Ribrag Laurence Zitvogel |
| author_facet | Camille Bigenwald Yacine Haddad Cassandra Thelemaque Agathe Carrier Roxanne Birebent Pierre Ly Caroline Flament Imran Lahmar Eric de Sousa Markus Maeurer Makoto Miyara Tarek Assi Cristina Castilla-Llorente Christophe Willekens Céline Fayemi Julien Lazarovici Aurélien Marabelle Lisa Derosa Vincent Ribrag Laurence Zitvogel |
| author_sort | Camille Bigenwald |
| collection | DOAJ |
| description | The SARS-CoV-2 pandemic still represents a threat for immunosuppressed and hematological malignancy (HM) bearing patients, causing increased morbidity and mortality. Given the low anti-SARSCoV-2 IgG titers post-vaccination, the COVID-19 threat prompted the prophylactic use of engineered anti-SARS-CoV-2 monoclonal antibodies. In addition, potential clinical significance of T cell responses has been overlooked during the first waves of the pandemic, calling for additional in-depth studies. We reported that the polarity and the repertoire of T cell immune responses govern the susceptibility to SARS-CoV-2 infection in health care workers and solid cancer patients. Here, we longitudinally analyzed humoral and cellular immune responses at each BNT162b2 mRNA vaccine injection in 47 HM patients under therapy. Only one-third of HM, mostly multiple myeloma (MM) bearing patients, could mount S1-RBD-specific IgG responses following BNT162b2 mRNA vaccines. This vaccine elicited a S1-RBD-specific Th1 immune response in about 20% patients, mostly in MM and Hodgkin lymphoma, while exacerbating Th2 responses in the 10% cases that presented this recognition pattern at baseline (mostly rituximab-treated patients). Performing a third booster barely improved the percentage of patients developing an S1-RBD-specific Th1 immunity and failed to seroconvert additional HM patients. Finally, 16 patients were infected with SARS-CoV-2, of whom 6 developed a severe infection. Only S1-RBD-specific Th1 responses were associated with protection against SARS-CoV2 infection, while Th2 responses or anti-S1-RBD IgG titers failed to correlate with protection. These findings herald the paramount relevance of vaccine-induced Th1 immune responses in hematological malignancies. |
| format | Article |
| id | doaj-art-e42eb58d71344cc7b958ed1f06d3f934 |
| institution | Kabale University |
| issn | 2162-402X |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-e42eb58d71344cc7b958ed1f06d3f9342024-12-27T17:34:39ZengTaylor & Francis GroupOncoImmunology2162-402X2023-12-0112110.1080/2162402X.2022.2163785RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignanciesCamille Bigenwald0Yacine Haddad1Cassandra Thelemaque2Agathe Carrier3Roxanne Birebent4Pierre Ly5Caroline Flament6Imran Lahmar7Eric de Sousa8Markus Maeurer9Makoto Miyara10Tarek Assi11Cristina Castilla-Llorente12Christophe Willekens13Céline Fayemi14Julien Lazarovici15Aurélien Marabelle16Lisa Derosa17Vincent Ribrag18Laurence Zitvogel19Gustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceImmunoTherapy/ ImmunoSurgery, Champalimaud Centre for the Unknown, Lisboa, PortugalImmunoTherapy/ ImmunoSurgery, Champalimaud Centre for the Unknown, Lisboa, PortugalCentre d’Immunologie et des Maladies Infectieuses (CIMI-Paris), Assistance Publique Hôpitaux de Paris (AP-HP), Hôpital Pitié-Salpêtrière, Paris, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceHematology Department, Gustave Roussy Cancer Campus, Villejuif, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceGustave Roussy Cancer Campus (GRCC), Villejuif Cedex, FranceThe SARS-CoV-2 pandemic still represents a threat for immunosuppressed and hematological malignancy (HM) bearing patients, causing increased morbidity and mortality. Given the low anti-SARSCoV-2 IgG titers post-vaccination, the COVID-19 threat prompted the prophylactic use of engineered anti-SARS-CoV-2 monoclonal antibodies. In addition, potential clinical significance of T cell responses has been overlooked during the first waves of the pandemic, calling for additional in-depth studies. We reported that the polarity and the repertoire of T cell immune responses govern the susceptibility to SARS-CoV-2 infection in health care workers and solid cancer patients. Here, we longitudinally analyzed humoral and cellular immune responses at each BNT162b2 mRNA vaccine injection in 47 HM patients under therapy. Only one-third of HM, mostly multiple myeloma (MM) bearing patients, could mount S1-RBD-specific IgG responses following BNT162b2 mRNA vaccines. This vaccine elicited a S1-RBD-specific Th1 immune response in about 20% patients, mostly in MM and Hodgkin lymphoma, while exacerbating Th2 responses in the 10% cases that presented this recognition pattern at baseline (mostly rituximab-treated patients). Performing a third booster barely improved the percentage of patients developing an S1-RBD-specific Th1 immunity and failed to seroconvert additional HM patients. Finally, 16 patients were infected with SARS-CoV-2, of whom 6 developed a severe infection. Only S1-RBD-specific Th1 responses were associated with protection against SARS-CoV2 infection, while Th2 responses or anti-S1-RBD IgG titers failed to correlate with protection. These findings herald the paramount relevance of vaccine-induced Th1 immune responses in hematological malignancies.https://www.tandfonline.com/doi/10.1080/2162402X.2022.2163785COVID-19vaccinationT cell |
| spellingShingle | Camille Bigenwald Yacine Haddad Cassandra Thelemaque Agathe Carrier Roxanne Birebent Pierre Ly Caroline Flament Imran Lahmar Eric de Sousa Markus Maeurer Makoto Miyara Tarek Assi Cristina Castilla-Llorente Christophe Willekens Céline Fayemi Julien Lazarovici Aurélien Marabelle Lisa Derosa Vincent Ribrag Laurence Zitvogel RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies OncoImmunology COVID-19 vaccination T cell |
| title | RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies |
| title_full | RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies |
| title_fullStr | RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies |
| title_full_unstemmed | RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies |
| title_short | RBD- specific Th1 responses are associated with vaccine-induced protection against SARS-CoV-2 infection in patients with hematological malignancies |
| title_sort | rbd specific th1 responses are associated with vaccine induced protection against sars cov 2 infection in patients with hematological malignancies |
| topic | COVID-19 vaccination T cell |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2022.2163785 |
| work_keys_str_mv | AT camillebigenwald rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT yacinehaddad rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT cassandrathelemaque rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT agathecarrier rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT roxannebirebent rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT pierrely rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT carolineflament rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT imranlahmar rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT ericdesousa rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT markusmaeurer rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT makotomiyara rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT tarekassi rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT cristinacastillallorente rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT christophewillekens rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT celinefayemi rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT julienlazarovici rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT aurelienmarabelle rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT lisaderosa rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT vincentribrag rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies AT laurencezitvogel rbdspecificth1responsesareassociatedwithvaccineinducedprotectionagainstsarscov2infectioninpatientswithhematologicalmalignancies |